Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban) …

T Lanitis, FE Cotté, AF Gaudin, I Kachaner… - Journal of medical …, 2014 - Taylor & Francis
Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

[PDF][PDF] T. Lanitis

FE Cotte, AF Gaudin, I Kachaner… - Journal of Medical …, 2014 - researchgate.net
Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban) …

T Lanitis, FE Cotté, AF Gaudin… - Journal of medical …, 2014 - pubmed.ncbi.nlm.nih.gov
Objectives To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban) …

T Lanitis, FE Cotté, AF Gaudin, I Kachaner… - Journal of Medical …, 2014 - europepmc.org
Objectives To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …